Table 4.

Predictors of the Co-Occurrence of EDS and Hypertension

Predictors	Model 1		Model 2		Model 3
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Ach	0.971 (0.948~0.994)	0.016	0.966 (0.939~0.994)	0.019	0.932 (0.868~1.000)	0.049
NE	1.002 (0.998~1.005)	0.415	1.001 (0.996~1.006)	0.735	0.999 (0.990~1.000)	0.913
SOD	1.011 (0.971~1.052)	0.594	1.040 (0.977~1.108)	0.216	0.964 (0.873~1.065)	0.472
IL-6	1.823 (0.870~3.820)	0.112	1.943 (0.721~5.233)	0.189	1.951 (0.418~9.101)	0.395
ET-1	1.108 (0.905~1.356)	0.322	1.126 (0.870~1.457)	0.367	1.125 (0.770~1.644)	0.544
TNF-α	1.003 (0.979~1.027)	0.835	0.988 (0.955~1.022)	0.487	0.976 (0.918~1.036)	0.422

Notes: Values that are associated with P values <0.05 are given in bold. OR and P values of the logistic regression models with plasma biomarkers as predictors, the co-occurrence of EDS and hypertension as outcomes. ESS score greater than or equal to 13 was used to define EDS. Hypertension was defined as a awake systolic blood pressure≥140mm Hg. Model 1: unadjusted analysis; Model 2: adjusted for age, sex, BMI neck and waist circumference, smoking history, alcohol drinking; Model 3: adjusted for age, sex, BMI neck and waist circumference, smoking history, alcohol drinking and relevant sleep covariables, including AHI, AI, sleep-onset latency, TST, ODI, MSpO₂.

Abbreviations: EDS, excessive daytime sleepiness; Ach, acetylcholine; NE, norepinephrine; SOD, superoxide dismutase; IL-6, interleukin-6; ET-1, endothelin-1; TNF-α, tumor necrosis factor-α; OR, odds ratio; CI, confidence interval.